Myeloproliferative Disorders, Pulmonary Hypertension
Conditions
Brief summary
This is an observational prospective study aiming to clarify the prevalence of pulmonary hypertension in patients with Myeloproliferative Neoplasms and their prognosis. All patients attending our department with the above mentioned neoplasms will be offered inclusion in this study. All will have an echo performed and patients identified as being at risk of pulmonary hypertension will be offered complete investigation as specified by the European Cardiology Association. All patients will be followed up for a total of five years to identify prognosis.
Interventions
RADIATIONRadiology
Only a small subsample will require CT and right heart catherisation
Sponsors
Odense University Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Myeloproliferative Neoplasms (PV, ET, PMF according to WHO classification)
Exclusion criteria
* Pregnancy * Lack of informed consent * Age \< 18 years * Cognitive dysfunctions
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Prevalence of pulmonary hypertension at initial presentation and first echo | Initial recruitment |
Secondary
| Measure | Time frame |
|---|---|
| Mortality | 1 and 5 years |
| Incidence of pulmonary hypertension while under follow-up | 5 years |
Countries
Denmark
Outcome results
None listed